Podcast Episodes
Back to Search358: FDA's gene therapy turmoil, and an alternative model for funding research
We discuss the tragic news that a second teenage boy with Duchenne muscular dystrophy died after taking Sarepta Therapeutics' gene therapy, raising r…
1 year, 4 months ago
357: The upheaval of CDC's vaccine panel, and drug pricing confusion
First, we chat about how pharma companies still don’t have much clarity on Trump’s most-favored nation drug pricing policy, biotech’s next big takeou…
1 year, 4 months ago
356: An AI experiment at the FDA & Novo trailing in the obesity drug race
The FDA has rolled out an internal AI tool called Elsa that, unlike its namesake Disney character, can’t seem to let go of mistakes. Our colleague Br…
1 year, 4 months ago
355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview
The American Society of Clinical Oncology, or ASCO, kicks off its annual meeting this weekend in Chicago. We discuss what to watch at the meeting. Th…
1 year, 4 months ago
354: Uncertainty in CRISPR world and the start of more M&A
We chat about M&A deals picking up, leadership changes at Novo, and recent FDA advisory committee meetings for cancer drugs. We also bring on STAT re…
1 year, 4 months ago
353: Trump's drug-pricing plan and a potential Theranos 2.0
We chat about the mixed sentiment in biotech markets these days and a new blood-testing company formed by Elizabeth Holmes' husband. We also bring on…
1 year, 5 months ago
352: A firebrand takes oversight of vaccines, gene therapies
Matt Herper joins Adam and Allison to examine Prasad's appointment and the band of outsiders now in charge of U.S. health agencies. He and Adam debat…
1 year, 5 months ago
351: It's gonna be May (in biotech)
On this week’s episode of the Readout LOUD, we review President Trump’s first 100 days, the return of biotech M&A, strong drug launches, and Eli Lill…
1 year, 5 months ago
350: Pharma tariffs, and a 'sunshine day' for biotech stocks
How did Ireland become a hotspot for pharmaceutical manufacturing? What are the products that will come out of Flagship's latest startup centered aro…
1 year, 5 months ago
349: BIO's John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding
John Crowley, the CEO of industry lobbying group BIO, joins us to discuss the layoffs at the Food and Drug Administration, RFK Jr.'s comments on Nova…
1 year, 6 months ago